Perhaps they have a relationship with a mfg company with capacity. But it costs money to produce. They cannot enter into further debt by asking the mfg to credit them for raw mtls and services without permission from the court. Cannot take on further debt while under BK protection without court approval. Must be something out there I haven't seen. Court would not approve CLSC plan, to have them pay exorbitant monthly debt fees without allowing them an avenue to get product produced. In my experience with contract drug mfgs, they will not take on a job for an unproven product without agreement and cash up front. Always one of the toughest steps for a pharma research company going from clinical to commercial stages of product life cycle. I consult in the industry and have seen many patents get sold for the quick cash versus the headaches and costs of product development and commercial mfg logistics - even for solvent companies.
News 
Market Data 
Discover 
